Swiss biopharmaceutical company — Ferring Pharmaceuticals — summed up the selection of technological projects based on corporate accelerator GenerationS by RVC. The winning team selected by the expert jury will receive a cash prize of 10,000 euro for the development of their project.
The selection of innovative projects began in April 2019. More than 70 start-ups from Russia, Ukraine, Estonia, Kazakhstan, Armenia, Uzbekistan, and India were considered.
Eight teams went to the selection final, offering the most promising solutions in the field of new peptide technologies, oocyte maturation media, 3d technologies bioprinting, decision support systems for specialists of centers of assisted reproductive technologies (ART) and others. Some of the finalists will have an opportunity to continue cooperation with the company at the global level for the further development and implementation of projects.
Recognized specialists in the field of reproductive medicine, prominent representatives of science and business, whose experience makes it possible to assess the prospects of both Russian and international developments, took part in the evaluation of projects.
The expert jury selected the winning team, which will receive 10,000 euro for the development of technology. The project offers unique environments for vitrification of ovarian tissue to preserve fertility and conduct menopausal hormone therapy in patients of different age groups. With the support of leading specialists of the Ferringcompany, the team will be able to bring its decision to a commercial product.
GenerationS is a platform for the development of corporate innovation, the largest corporate accelerator in Russia and the CIS. Organized by RVC in 2013. GenerationS implements comprehensive programs for the development of corporations: intracorporate — on the development of internal entrepreneurship; acceleration — on scouting and acceleration of external projects; international — to train employees in the methods of building and conducting innovations based on corporations — global leaders.To date, the accelerator infrastructure includes over 16 thousand start-ups from more than 30 countries and about 400 corporate and ecosystem partners. In 2018, GenerationS became the first Russian accelerator accredited by the Global Accelerator Network (GAN), organized by Techstars and became the best corporate accelerator in Europe, according to the Corporate Start-up Summit. In 2019, GenerationS entered the TOP-5 of the best state accelerators in the world, according to UBI Global.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a biopharmaceutical company that seeks, develops and markets innovative products in areas such as reproductive health, oncology, urology, gastroenterology, endocrinology, and orthopedics. A common goal connects the research activities and products of the company — to create specialized medicines that can fight various diseases and pathologies, using the resources and functional potential of the body. Company marketing, medical services, retail and wholesale divisions of the Ferring Company work in almost 60 countries, and management is carried out from the head office in the city of Saint-Preux, Switzerland.